Zevra Therapeutics Extends MIPLYFFA Exclusivity to 2041, Shares Jump 14%
ZVRA•Zevra Therapeutics secured an Orange Book-listed patent extending MIPLYFFA’s exclusivity until November 2041, blocking generic competition. MIPLYFFA net revenue jumped to $87.4 million in 2025 from $10.1 million in 2024, driving an $83.2 million net profit and prompting a Cantor Fitzgerald price target increase to $34 with shares up 14%.
1. Patent extension secures long-term exclusivity
Zevra submitted a new patent for listing in the FDA’s Orange Book, ensuring MIPLYFFA remains protected from generic competition until November 2041. This Orange Book listing grants procedural tools that automatically delay generic approvals if challenged, safeguarding market share for over 15 years.
2. Financial performance of MIPLYFFA
MIPLYFFA generated $87.4 million in net revenue in 2025, up from $10.1 million in 2024, and represented more than 82% of Zevra’s total $106.5 million revenue. The strong launch converted a prior-year net loss into an $83.2 million net profit for the full year 2025.
3. Analyst upgrade and investor reaction
Cantor Fitzgerald raised its price target on Zevra to $34 from $24 and maintained an Overweight rating, citing the exclusivity extension’s positive impact on cash flow projections. Shares surged 14% on the announcement, while retail sentiment shifted bullish and investors eye potential European approval and a pending patent-term extension.
